HK1255209A1 - 用於采用聚合物囊泡递送基因编辑工具的组合物和方法 - Google Patents

用於采用聚合物囊泡递送基因编辑工具的组合物和方法 Download PDF

Info

Publication number
HK1255209A1
HK1255209A1 HK18114337.3A HK18114337A HK1255209A1 HK 1255209 A1 HK1255209 A1 HK 1255209A1 HK 18114337 A HK18114337 A HK 18114337A HK 1255209 A1 HK1255209 A1 HK 1255209A1
Authority
HK
Hong Kong
Prior art keywords
gene editing
delivery
compositions
methods
editing tools
Prior art date
Application number
HK18114337.3A
Other languages
English (en)
Chinese (zh)
Inventor
P. Peter Ghoroghchian
Jivan Namdeo YEWLE
Original Assignee
Poseida Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics, Inc. filed Critical Poseida Therapeutics, Inc.
Publication of HK1255209A1 publication Critical patent/HK1255209A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK18114337.3A 2015-07-02 2016-07-01 用於采用聚合物囊泡递送基因编辑工具的组合物和方法 HK1255209A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562187942P 2015-07-02 2015-07-02
US62/187,942 2015-07-02
US201662322346P 2016-04-14 2016-04-14
US62/322,346 2016-04-14
US15/199,021 US20170000743A1 (en) 2015-07-02 2016-06-30 Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
US15/199,021 2016-06-30
PCT/US2016/040673 WO2017004509A1 (en) 2015-07-02 2016-07-01 Compositions and methods for delivery of gene editing tools using polymeric vesicles

Publications (1)

Publication Number Publication Date
HK1255209A1 true HK1255209A1 (zh) 2019-08-09

Family

ID=57609243

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114337.3A HK1255209A1 (zh) 2015-07-02 2016-07-01 用於采用聚合物囊泡递送基因编辑工具的组合物和方法

Country Status (8)

Country Link
US (1) US20170000743A1 (https=)
EP (1) EP3317414A4 (https=)
JP (2) JP6993966B2 (https=)
CN (1) CN108699563A (https=)
AU (1) AU2016288237B2 (https=)
CA (1) CA2991109A1 (https=)
HK (1) HK1255209A1 (https=)
WO (1) WO2017004509A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
US11213594B2 (en) 2016-04-29 2022-01-04 Poseida Therapeutics, Inc. Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
CA3036926C (en) 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
ES3051391T3 (en) 2016-10-06 2025-12-29 Poseida Therapeutics Inc Inducible caspases and methods for use
JP2020523383A (ja) 2017-06-14 2020-08-06 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性ｔ細胞受容体の標的置換
CA3124103A1 (en) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
US20220372105A1 (en) 2019-09-05 2022-11-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
AU2020407235A1 (en) 2019-12-20 2022-07-07 Poseida Therapeutics, Inc. Anti-MUC1 compositions and methods of use
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
GB202004254D0 (en) 2020-03-24 2020-05-06 Puridify Ltd Characterization of gene therapy vectors
EP4298205A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
CN117355607A (zh) * 2021-04-13 2024-01-05 阿森纳生物科学公司 非病毒同源性介导的末端连接
EP4413141A1 (en) 2021-10-04 2024-08-14 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
EP4482967A1 (en) 2022-02-23 2025-01-01 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2023193665A1 (zh) * 2022-04-07 2023-10-12 威海纽兰生物科技有限公司 基于细胞外囊泡酯酶响应药物递送载体及其制备方法和用途
EP4646189A1 (en) * 2023-01-06 2025-11-12 Vianautis Bio Limited Polymersomes for delivery of nucleic acid cargoes
EP4669746A1 (en) 2023-02-21 2025-12-31 Poseida Therapeutics, Inc. COMPOSITIONS AND GENOMIC EDITING PROCESSES
KR20250166122A (ko) 2023-02-21 2025-11-27 포세이다 테라퓨틱스, 인크. 게놈 편집을 위한 조성물 및 방법
CN121335979A (zh) 2023-05-17 2026-01-13 波西达治疗公司 靶向hbg1和hbg2的组合物及其使用方法
WO2025096980A1 (en) 2023-11-02 2025-05-08 Poseida Therapeutics, Inc. Compositions targeting klkb1 and methods of use thereof
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089579A2 (en) * 2000-05-19 2001-11-29 Regents Of The University Of Minnesota Composition for delivery of compounds to cells
US20040265835A1 (en) * 2003-06-30 2004-12-30 Lemaster David M. Method of sorting vesicle-entrapped, coupled nucleic acid-protein displays
CA2756670A1 (en) * 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
TWI576432B (zh) * 2009-04-07 2017-04-01 陶氏農業科學公司 序列特異性核酸酶之奈米粒子媒介式遞送技術
WO2011106376A2 (en) * 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
CA2792035A1 (en) * 2010-03-02 2011-09-09 Vindico Nanobio Technology, Inc. Compositions and methods for treating or preventing immuno-inflammatory disease
US20140363496A1 (en) 2011-01-07 2014-12-11 Vindico NanoBio Technology Inc. Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
AU2012249390B2 (en) * 2011-04-27 2017-03-30 Amyris, Inc. Methods for genomic modification
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
RU2662932C2 (ru) * 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
WO2014194190A1 (en) * 2013-05-30 2014-12-04 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
EP3155116A4 (en) 2014-06-10 2017-12-27 Massachusetts Institute Of Technology Method for gene editing

Also Published As

Publication number Publication date
EP3317414A4 (en) 2019-03-13
EP3317414A1 (en) 2018-05-09
CN108699563A (zh) 2018-10-23
CA2991109A1 (en) 2017-01-05
AU2016288237A1 (en) 2018-01-25
WO2017004509A1 (en) 2017-01-05
JP2019165745A (ja) 2019-10-03
US20170000743A1 (en) 2017-01-05
JP2018532408A (ja) 2018-11-08
JP6993966B2 (ja) 2022-02-04
AU2016288237B2 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
HK1255209A1 (zh) 用於采用聚合物囊泡递送基因编辑工具的组合物和方法
WO2015191693A3 (en) Method for gene editing
AU2017277731A1 (en) Hybrid carriers for Nucleic Acid cargo
EP3554546A4 (en) METHODS AND COMPOSITIONS FOR ADMINISTRATION OF NUCLEIC ACID AND PROTEIN PAYLOADS
WO2016205749A8 (en) Novel crispr enzymes and systems
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
EP3699280A3 (en) Novel cas9 systems and methods of use
EP4434997A3 (en) Delivery of negatively charged proteins using cationic lipids
EP3303607A4 (en) Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
EP4257690A3 (en) Crispr hybrid dna/rna polynucleotides and methods of use
WO2014205192A3 (en) Targeted integration
EP3230445A4 (en) Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
CA2884084C (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
HK1246316A1 (zh) 细胞因子融合蛋白
WO2016033315A3 (en) Synthon formation
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
WO2017070632A3 (en) Nucleobase editors and uses thereof
WO2016046778A3 (en) Protease-activatable bispecific proteins
EP3115457A4 (en) Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
HK1256817A1 (zh) 用於基因组编辑的组合物和方法
WO2019135816A3 (en) Novel nucleic acid modifiers
WO2015052231A3 (en) Multiplex editing system
MX363017B (es) Métodos y productos para la expresión de proteínas en células.
WO2014035475A8 (en) Methods to control protein heterogeneity
WO2013006544A8 (en) Methods for making multimeric polypeptides